25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 25,583 shares of the biotechnology company’s stock, valued at approximately $192,000.

Several other institutional investors and hedge funds also recently bought and sold shares of BCRX. Venturi Wealth Management LLC purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $46,000. R Squared Ltd bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $48,000. KBC Group NV grew its stake in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares during the last quarter. Quantinno Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $82,000. Finally, SkyView Investment Advisors LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BCRX shares. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI increased their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, Needham & Company LLC increased their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.71 on Thursday. The stock’s fifty day moving average price is $8.15 and its 200 day moving average price is $7.86. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -12.64 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the prior year, the company earned $0.28 earnings per share. The business’s revenue for the quarter was up 40.8% compared to the same quarter last year. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.